You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

ADDERALL 10 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Adderall 10 patents expire, and when can generic versions of Adderall 10 launch?

Adderall 10 is a drug marketed by Teva Womens and is included in one NDA.

The generic ingredient in ADDERALL 10 is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. There are fifty-five drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ADDERALL 10?
  • What are the global sales for ADDERALL 10?
  • What is Average Wholesale Price for ADDERALL 10?
Drug patent expirations by year for ADDERALL 10
Recent Clinical Trials for ADDERALL 10

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Boston Children's HospitalPhase 1
The Beckwith InstitutePhase 4
Eva SzigethyPhase 4

See all ADDERALL 10 clinical trials

US Patents and Regulatory Information for ADDERALL 10

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Womens ADDERALL 10 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate TABLET;ORAL 011522-007 Feb 13, 1996 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ADDERALL 10

See the table below for patents covering ADDERALL 10 around the world.

Country Patent Number Title Estimated Expiration
Mexico PA02000290 FORMA DE DOSIFICACION ORAL DE LIBERACION INMEDIATA RAPIDA. (RAPID IMMEDIATE RELEASE ORAL DOSAGE FORM.) ⤷  Sign Up
Canada 2378336 ⤷  Sign Up
European Patent Office 1202739 ⤷  Sign Up
Australia 6089200 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.